biOasis Announces Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

pdficon_small Download this as a PDF

March 20th, 2017, Vancouver, BC

biOasis Technologies Inc. (TSX.V: BTI) (the “Company”) announces a nonbrokered private placement of up to 4,500,000 units at a price of $0.70 per unit of gross proceeds of up to $3,150,000 (the “Offering”). Each unit will consist of one common share and one-half common share purchase warrant. Each whole warrant entitles the holder to purchase one additional common share of the Company at a price of $1.00 per share for a period of twenty-four months from the date of closing, subject to an exercise acceleration clause. Under the exercise acceleration clause, which the Company may exercise once the Units are free of resale restrictions and if the Company’s shares are trading at or above a volume weighted average price of $1.50 for 10 consecutive trading days, the Warrants will expire upon 30 days from the date the Company provides notice in writing to the Warrant holders via a news release.

The proceeds from the sale of units will be added to working capital in furtherance of the Company’s business. A finder’s fee of up to 8% of the proceeds from the sale of units may be paid in cash in connection with the private placement. The Offering is expected to close in tranches and the securities to be issued under the Offering will be subject to a four-month hold period from the date of closing of each tranche. The Offering is subject to the acceptance of the TSX Venture Exchange.

“This is the first equity raise since August of 2014 and since then we’ve made major
advancements with our technology, most notably the discovery of the peptide (Transcendpep) that has provided security to our technology out to 2034. Provided this capital is realized, it will provide the resources to obtain extremely valuable initial human data.”, said Rob Hutchison CEO.

About biOasis
biOasis Technologies Inc. is a biopharmaceutical company headquartered in Vancouver,
Canada. Based on Transcend, biOasis proprietary brain delivery platform, the company is
focused on creating new drugs that can cross the BBB to address unmet medical needs in the treatment of brain diseases such as neurodegeneration, metastatic cancer and metabolic diseases. biOasis trades on the OTCQX under the symbol “BIOAF” and on the TSX Venture Exchange under the symbol “BTI”. For more information about the company please visit www.bioasis.ca.

Forward Looking Statements
Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words “believe”, “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of any product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval
to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: products that we develop may not
succeed in preclinical or clinical trials, or future products in our targeted corporate objectives; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and the costs of launching our products may be greater than anticipated; we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from
pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward- looking statements and information to reflect subsequent events or circumstances, except as required by law.

On Behalf of the Board of Directors
Rob Hutchison Chairman & CEO

“Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is
defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release”

Company Contact
Rob Hutchison
biOasis Technologies Inc.
info@bioasis.ca
1-604-644-1232

By | 2017-04-10T09:01:42+00:00 Monday, March 20, 2017|2017 Press Releases, Corporate Press Releases|